within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG13_Teprotumumab;
model Teprotumumab 
   extends Pharmacolibrary.Drugs.ATC.L.L04AG13;

  annotation(Documentation(
    info ="<html><body><p>Teprotumumab is a human monoclonal antibody that acts as an insulin-like growth factor-1 receptor (IGF-1R) inhibitor. It is specifically approved for the treatment of thyroid eye disease (TED), an autoimmune condition associated with Graves' disease. The drug was approved by the FDA in 2020 and is currently in use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with thyroid eye disease following intravenous infusion.</p><h4>References</h4><ol><li><p>Xin, Y, et al., &amp; Ramanathan, S (2021). Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease. <i>Clinical pharmacokinetics</i> 60(8) 1029–1040. DOI:<a href=&quot;https://doi.org/10.1007/s40262-021-01003-3&quot;>10.1007/s40262-021-01003-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33768488/&quot;>https://pubmed.ncbi.nlm.nih.gov/33768488</a></p></li><li><p>Fleuren, ED, et al., &amp; van der Graaf, WT (2013). The strength of small: improved targeting of insulin-like growth factor-1 receptor (IGF-1R) with F(ab&#x27;)₂-R1507 fragments in Ewing sarcomas. <i>European journal of cancer (Oxford, England : 1990)</i> 49(13) 2851–2858. DOI:<a href=&quot;https://doi.org/10.1016/j.ejca.2013.04.009&quot;>10.1016/j.ejca.2013.04.009</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23664098/&quot;>https://pubmed.ncbi.nlm.nih.gov/23664098</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Teprotumumab;
